Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples

International Journal of Oncology

Volumn 28, Issue 5, 2006, Pages 1099-1103

  Stock, Wendy ^a   Yu, Daohai ^b   Karrison, Ted ^a   Sher, Dorie ^a   Stone, Richard M ^b   Larson, Richard A ^a   Bloomfield, Clara D ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NONE

Author keywords

BCR ABL; Blood and bone marrow analysis; Chronic myelogenous leukemia; Molecular monitoring; Quantitative real time RT PCR

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CYTARABINE; HARRINGTONINE DERIVATIVE; HOMOHARRINGTONINE; PRIMER DNA;

ARTICLE; BLOOD; BONE MARROW; CHRONIC MYELOID LEUKEMIA; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METHODOLOGY; MONITORING; NUCLEOTIDE SEQUENCE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; BONE MARROW; CYTARABINE; DNA PRIMERS; FUSION PROTEINS, BCR-ABL; HARRINGTONINES; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MONITORING, PHYSIOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC;

EID: 33646825057     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.5.1099     Document Type: Article

References (20)

1. Stock W, Westbrook CA, Peterson B, et al: Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 15: 26-36, 1997.
2. Ayscue LH, Ross DW, Ozer H, Rao K, Gulley ML and Dent GA: Bcr/abl recombinant DNA analysis versus karyotype in the diagnosis and therapeutic monitoring of chronic myeloid leukemia. Am J Clin Pathol 94: 404-409, 1990.
3. Grossman A, Silver RT, Szatrowski TP, Gutfriend A, Verma RS and Benn PA: Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia. Leukemia 5: 540-547, 1991.
4. Reiter A, Skladny H, Hochhaus A, et al: Molecular response of CML patients treated with interferon-alpha monitored by quantitative Southern blot analysis. German chronic myeloid leukaemia (CML) Study Group. Br J Haematol 97: 86-93, 1997.
5. Radich JP, Gooley T, Bryant E, et al: The significance of bcr-abl molecular detection in chronic myeloid leukemia patients 'late', 18 months or more after transplantation. Blood 98: 1701-1707, 2001.
6. Eder M, Battmer K, Kafert S, Stucki A, Ganser A and Hertenstein B: Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation. Leukemia 13: 1383-1389, 1999.
7. Preudhomme C, Revillion F, Merlat A, et al: Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real-time' quantitative RT-PCR assay. Leukemia 13: 957-964, 1999.
8. Martinelli G, Montefusco V, Testoni N, et al: Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation. Haematologica 85: 653-658, 2000.
9. Olavarria E, Kanfer E, Szydlo R, et al: Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 97: 1560-1565, 2001.
10. Hughes TP, Kaeda J, Branford S, et al: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349: 1423-1432, 2003.
11. Bland JM and Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet i: 307-310, 1986.
12. Gallagher RE, Yeap BY, Bi W, et al: Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 101: 2521-2528, 2003.
13. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994-1004, 2003.
14. Lee WI, Kantarjian H, Glassman A, Talpaz M and Lee MS: Quantitative measurement of BCR/abl transcripts using real-time polymerase chain reaction. Ann Oncol 13: 781-788, 2002.
15. Merx K, Muller MC, Kreil S, et al: Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 16: 1579-1583, 2002.
16. Wang L, Pearson K, Pillitteri L, Ferguson JE and Clark RE: Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 118: 771-777, 2002.
17. Wu CJ, Neuberg D, Chillemi A, et al: Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leuk Lymphoma 43: 2281-2290, 2002.
18. Shah NP, Tran C, Lee FY, Chen P, Norris D and Sawyers CL: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401, 2004.
19. Marin D, Kaeda JS, Andreasson C, et al: Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 103: 1850-1855, 2005.
20. O'Dwyer ME, Gatter KM, Loriaux M, et al: Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 17: 481-487, 2003.